A genome-wide in vivo screen reveals fitness pathways required for streptococcal infective endocarditis

This study presents the first genome-wide in vivo screen identifying 146 conserved *Streptococcus* genes and pathways essential for infective endocarditis fitness, revealing broad evolutionary conservation and novel targets for multi-target antimicrobial strategies.

The Gist

Imagine your heart is a bustling city. Usually, it's a well-protected fortress. But sometimes, a tiny crack in the wall (a damaged heart valve) lets a few bad actors—bacteria called Streptococcus—slip inside. Once they get in, they don't just sit there; they build a fortified castle (a vegetation) on the heart valve and start throwing a massive, destructive party. This disease is called Infective Endocarditis (IE), and it's deadly.

For a long time, doctors and scientists knew that these bacteria caused the disease, but they didn't really know how they pulled it off. It was like knowing a thief broke into a house, but not knowing which tools they used to pick the lock or how they stayed hidden.

This paper is like a massive, high-tech "surveillance operation" that finally caught the thieves red-handed and listed every single tool in their toolkit.

Here is the story of how they did it, broken down into simple parts:

1. The Great "Who's Missing?" Game

The researchers had a library of over 2,000 different versions of the bacteria. In each version, they had turned off (deleted) exactly one gene. Think of a gene as a single instruction in a recipe book. If you delete the "add salt" instruction, the soup tastes weird. If you delete the "add flour" instruction, the cake collapses.

They mixed all these "broken" bacteria together and injected them into rabbits with damaged heart valves. Then, they waited 20 hours and checked the heart.

• The Question: Which bacteria were still there, partying and building their castle? Which ones had died out or failed to grow?
• The Result: They found 146 specific genes that the bacteria absolutely needed to survive in the heart. If you broke any of these 146 parts, the bacteria couldn't infect the heart.

2. The "New" Tools

The most exciting part? 94% of these 146 genes were brand new discoveries.
Before this study, scientists only knew about a handful of tools the bacteria used. They thought they knew the thief's toolkit. This study revealed that the thief had a secret basement full of tools no one knew about.

• The Metaphor: Imagine you thought a burglar only used a crowbar and a flashlight. This study revealed they also used a specific type of lock-pick, a thermal camera, a walkie-talkie, and a special glue. We found 146 "special tools" we never knew existed.

3. The "Heart-Specific" vs. "Everyday" Tools

The researchers then asked: "Do these bacteria need these tools just to live in a petri dish (a lab), or do they only need them to survive in a heart?"

• The Everyday Tools: Some genes were like "eating" or "breathing." The bacteria needed them to live anywhere, whether in a lab or a heart.
• The Heart-Specific Tools: Many of the 146 genes were like specialized survival gear. For example, the bacteria needed to make their own specific vitamins (like the Shikimate pathway) or build a special type of armor (Rhamnan) only when they were in the heart. In a lab dish, they could just grab these things from the environment, but in the heart, they had to make them from scratch.
• Why this matters: If we can design a drug that stops the bacteria from making these "Heart-Specific Tools," we can kill the infection without hurting the bacteria when they are just hanging out in your mouth (which is good, because we need some good bacteria there).

4. The "Plan B" (Compensatory Mechanisms)

Here is where it gets really clever. The researchers tried to break the bacteria's "Plan A" (their main way of surviving) to see what happened.

• The Experiment: They broke the bacteria's ability to make a crucial fuel called CoA. The bacteria should have died, right?
• The Twist: The bacteria didn't die. They evolved! They found a "Plan B." They started pumping up their "Fatty Acid Factory" to compensate for the broken fuel line.
• The Metaphor: Imagine you cut off the main water pipe to a house. Instead of the house flooding or drying out, the residents quickly installed a giant rainwater collection system and a water filter. They found a workaround.
• The Lesson: Bacteria are incredibly adaptable. If we attack them with one drug, they might find a workaround. This study shows us that to win, we might need to attack them with multiple drugs at once (hitting the main pipe and the rainwater system) so they can't escape.

5. The "Universal" Thieves

The researchers also tested these findings on a different type of bacteria (Streptococcus mutans), which is a distant cousin of the first one.

• The Result: Even though these two bacteria are different species, they both used the same 146 tools to infect the heart.
• The Takeaway: This suggests that the "rules of the game" for infecting a heart are universal for these types of bacteria. A drug that works on one might work on the others.

Why Should You Care?

This paper is a roadmap for the future of medicine.

1. New Targets: We now have a list of 146 "Achilles' Heels" for these bacteria. Drug companies can use this list to design new antibiotics that specifically target these weaknesses.
2. Smarter Drugs: Because we know these bacteria can find "Plan B" workarounds, doctors can design treatments that block multiple paths at once, making it much harder for the bacteria to survive.
3. Less Collateral Damage: Since many of these tools are only used when the bacteria are in the heart (not in the mouth), we might be able to cure heart infections without wiping out the good bacteria in our mouths or causing antibiotic resistance in healthy people.

In short: Scientists finally mapped the entire "survival manual" of the bacteria that cause deadly heart infections. They found that these bacteria rely on a hidden set of tools to survive in the heart, and they are tricky enough to find workarounds if you only attack one tool. But now, we know exactly what to target to stop them for good.

Technical Summary

1. Problem Statement

Infective endocarditis (IE) is a life-threatening infection of the heart's endocardial surface, primarily caused by oral streptococci (e.g., Streptococcus sanguinis and Streptococcus mutans) entering the bloodstream. Despite high mortality rates (15–20% in-hospital), the genetic basis of IE virulence remains poorly defined. Previous studies have been limited to small-scale gene examinations or specific protein subsets (e.g., lipoproteins), failing to provide a comprehensive view of the bacterial genome. Furthermore, existing methods often suffer from "bottleneck effects" in pooled mutant screens, leading to inconsistent results, and lack insight into how bacteria adapt when key fitness pathways are disrupted. There is a critical need for a genome-wide, in vivo analysis to identify non-redundant fitness determinants and understand the physiological constraints of the cardiac niche.

2. Methodology

The authors employed a multi-stage, high-throughput approach combining a comprehensive mutant library with next-generation sequencing (NGS) and experimental evolution:

• Mutant Library: Utilized a S. sanguinis SK36 non-essential gene knockout library comprising 2,011 mutants, plus 27 newly annotated ORF knockouts and one essential gene mutant ($\Delta f_1f_o$), totaling 2,039 mutants.
• In Vivo Model: Used a rigorously optimized rabbit IE model. A catheter was inserted into the aortic valve to induce sterile vegetations. Bacteria were inoculated via the ear vein, and cardiac vegetations were harvested ~20 hours post-inoculation.
• Screening Strategy:
  • Pool Optimization: Tested various pool sizes (85, 159, 212 mutants) to avoid bottleneck effects. A pool size of ~159 mutants was selected as optimal.
  • ORFseq Platform: Used a sequencing-based method (ORFseq) that identifies mutants via ORF-linked APH(3')-IIIa (kanamycin resistance) tags.
  • Workflow: Conducted in three stages (Initial Screen, Re-screen, and Final Validation) across 24 pools and thousands of competitive fitness measurements.
  • Metrics: Fitness was quantified by the "abundance ratio" (mutant abundance in vegetations vs. input inoculum).
• Comparative & Evolutionary Studies:
  • Cross-Species Validation: Selected mutants were tested in S. mutans UA159 to assess conservation.
  • In Vitro vs. In Vivo: Mutants were grown in Brain Heart Infusion (BHI) media under physiological conditions (39°C, 12% O₂) to distinguish niche-specific requirements from general growth defects.
  • Experimental Evolution: Serial passage experiments were conducted on mutants with severe growth defects (e.g., coaA and shikimate pathway mutants) to identify compensatory "bypass" mechanisms via whole-genome sequencing (WGS).

3. Key Contributions

• First Genome-Wide In Vivo Screen: This is the first comprehensive analysis of bacterial fitness in a vertebrate IE model, moving beyond candidate gene approaches.
• Identification of 146 Fitness Determinants: The study identified 146 genes in S. sanguinis required for IE fitness. Crucially, 94% (137 genes) were previously unlinked to endocarditis.
• Discovery of Compensatory Mechanisms: The study revealed that disrupting key metabolic pathways triggers reproducible, adaptive "bypass" mechanisms, highlighting the plasticity of bacterial fitness networks.
• Conservation Analysis: Demonstrated that a core set of IE fitness factors is conserved across Streptococcus, Enterococcus, and Staphylococcus, suggesting broad therapeutic targets.

4. Key Results

• Novel Determinants: The 146 identified genes cluster into five functional categories: DNA replication/cell division, transcription/translation, cell wall synthesis, transport/metabolism, and hypothetical proteins.
• Pathway Specificity:
  • Niche-Specific Requirements: Genes in the shikimate pathway (aromatic amino acid biosynthesis) and serine biosynthesis were essential for IE fitness but dispensable for growth in rich media (BHI), indicating the cardiac vegetation is nutrient-limited.
  • Core Metabolic Dependencies: Coenzyme A (CoA) biosynthesis and rhamnan synthesis (cell wall) were critical. coaA mutants showed severe growth defects in vitro, while downstream coaB/C mutants were viable in vitro but failed in vivo.
  • Transport Systems: The SsaACB manganese transporter and Energy-Coupling Factor (ECF) transporters were vital for IE fitness.
• Cross-Species Conservation: When tested in S. mutans, mutants in CoA and shikimate pathways also showed severe IE fitness defects, confirming broad conservation between distantly related oral streptococci.
• Experimental Evolution Findings:
  • Shikimate Pathway: S. mutans mutants lacking shikimate genes (which had growth defects) evolved duplications of a peptide transporter gene cluster (SMU255–SMU259), suggesting increased peptide uptake compensates for the loss of aromatic amino acid synthesis.
  • CoA Biosynthesis: S. sanguinis $\Delta coaA$ mutants (growth-defective) evolved mutations in fabT (a repressor of fatty acid synthesis) and duplications of the FASII gene cluster. This indicates that upregulating fatty acid synthesis can compensate for impaired CoA synthesis.
• Therapeutic Targets: The study identified pathways (shikimate, CoA, rhamnan, ECF transporters) that are absent or divergent in humans, making them high-priority targets for novel antimicrobials.

5. Significance

• Redefining IE Pathogenesis: The findings shift the understanding of IE from a toxin-mediated disease to one driven by the sustained capacity of bacteria to adapt to nutrient limitation and immune pressure within cardiac vegetations.
• Drug Development: By identifying 146 fitness factors, many of which are conserved and essential in vivo but not in vitro, the study provides a "reservoir" of novel targets. The shikimate pathway, in particular, is highlighted as an ideal target due to its absence in humans and essentiality in IE.
• Overcoming Resistance: The identification of compensatory bypass mechanisms (e.g., peptide uptake or fatty acid synthesis upregulation) reveals the physiological constraints of the IE fitness landscape. This suggests that multi-target drug strategies (simultaneously inhibiting a primary pathway and its compensatory bypass) could prevent the emergence of resistance and effectively treat IE.
• Methodological Advancement: The study establishes a robust framework for genome-wide in vivo screening, overcoming previous limitations of bottleneck effects and providing a template for studying other systemic infections.